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Abstract: We report the synthesis and in vitro activity against T. cruzi epimastigotes of 
15 novel quinoxaline derivatives. Ten of the derivatives presented IC50 values lower 
than the reference drugs Nfx and Bzn; four of them standed out with IC50 values lower 
than 1.5 M. Moreover, unspecific cytotoxicity and genotoxicity studies are also 
reported. Compound 14 showed a SI higher than 24, whereas compound 10 was the 
only one that was negative in the genotoxicity screening. 
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Chagas disease (CD) is classified as one of the 17 Neglected Tropical Diseases (NTD) 
as defined by WHO.
1
 The 17 NTD account for a disease burden of at least 26 million 
disability-adjusted life years (DALYs) according to the Third WHO Report on 
Neglected Tropical Diseases
2
 and are under the Sustainable Development Goals SDG3. 
However, only the 0.6% of the new therapeutic products registered from 2000 to 2011 
were indicated for NTD and none of them were a NCE.
3
 These facts highlight the urgent 
need of new effective and safe drugs for fighting NTDs. 
CD, also known as American trypanosomiasis, is caused by the protozoan parasite 
Trypanosoma cruzi. It used to be considered as a zoonotic disease affecting rural areas 
in low-middle income countries in Latin America. Nevertheless, human migration has 
spread out the disease worldwide and, according to WHO, 8 million people are 
currently infected.
4
 It is estimated that over 10000 people die every year from CD, and 
more than 25 million people are at risk of infection. 
CD is curable if treatment is initiated soon after infection; therefore, access to diagnosis 
is essential. If not treated, 30% of the affected people develop heart damage and 10% 
suffer from digestive and/or neurological alterations. Nifurtimox (Lampit®) and 
Benznidazol (Rochagan®) are the only available drugs for CD and they were developed 
more than 40 years ago. Neither of them is approved by the FDA.
5
 The major limitation 
of currently available drugs is their lower antiparasitic activity in the established chronic 
form of the disease, which is the most prevalent presentation. On the other hand, both 
drugs have undesired side effects that can lead to treatment discontinuation, which for 
Nfx include anorexia, nausea and vomiting causing severe weight loss, insomnia and 
irritability, while for Bnz the most common adverse effect is urticarial dermatitis.
6, 7
 
Three clinical trials have recently been conducted. A phase II proof-of-activity study of 
oral posaconazole in the treatment of asymptomatic chronic CD was completed in 
January 2015 and no conclusions have been reported.
8
 The phase II clinical trial for the 
treatment of chronic CD with posaconazole and benznidazole (CHAGASAZOL) and a 
higher treatment failure was observed in patients in the posaconazole groups than in the 
Bnz group.
9, 10
 Finally, a proof-of-concept study of the promising NCE E1224 was 
recently completed but the development of E1224 as monotherapy has been stopped and 
it will be considered for new combinatory regimens.
5, 11, 12
 
This background justifies the urgent need for novel and better drugs to treat both acute 
and chronic phases. Quinoxaline derivatives are a chemical scaffold that has showed a 
wide spectrum of biological activities.
13
 Our group has vast experience in the synthesis 
and biological evaluation of quinoxaline derivatives with anti-cancer, anti-
mycobacterium and anti-inflammatory activities among others.
14-26
 One of the projects 
has been focused on the study of novel quinoxaline derivatives as anti T. cruzi agents. In 
this field, over 200 derivatives have been prepared and evaluated as anti-trypanosomatid 
agents and some structural requirements have been established for their anti-chagasic in 
vitro activity. 
20, 25, 27, 28
 Therefore, it can be considered that the main structural 
requirements for the trypanocidal activity of quinoxaline derivatives are: the presence of 
the N-oxide moiety and the insertion of electro withdrawing substituents on the 
quinoxaline ring (e.g. fluoro, chloro, trifluoromethyl…) Despite the general opinion 
about the toxicity associated with N-oxides, it has been reported that quinoxaline 
derivatives mutagenicity seems to be associated with the substituents on the 
heterocycle.
29
 With this background and with the aim of identifying a new lead with 
higher potency and selectivity and a better drug target profile a series of 15 novel 
quinoxaline derivatives were designed considering the structural requirements 
previously established by our group and the insertion of alicyclic amines of biological 
interest. Piperazine derivatives have been explored for their interest as anti-
trypanosomatid agents and their activity as inhibitors of different targets of interest to 
fight against CD has been reported.
30-32
 Structural similarity can be observed between 
the proposed compounds and fluoroquinolones (Figure 1), a family of well-known 





Figure 1. Structural similarity between fluoroquinolones (A) and proposed quinoxaline 
derivatives (B). 
The design, synthesis and in vitro evaluation of new quinoxaline derivatives (1-15) as 
antitrypanosomal agents are described and SARs are discussed. The non-specific 
toxicity against mammalian cells was studied in order to evaluate the quinoxaline 
selectivity to the parasites and the SOS/umu test was included as a preliminary 
genotoxicity screening assay. 
The designed compounds (1-15) were synthesized according to the sequence of 
reactions outlined in Scheme 1. 
 Scheme 1. Synthesis of quinoxaline derivatives 1-15. 
a) Previously reported in 27, 36; b) toluene, triethylamine, MW; c) acetonitrile, triethylamine, r.t.; d) N,N-
DMF, reflux. 
4 new quinoxaline 1,4-di-N-oxide derivatives (1-4) were prepared using a variation of 
the Beirut reaction using microwave irradiation in which the corresponding BFX 
reacted with the 1-(4-fluorophenyl)-4,4,4-trifluoro-1,3-butanedione using toluene as 
solvent and triethylamine as base. The use of microwave assisted organic synthesis 
reduced the reaction times and simplifies the purification of quinoxaline derivatives. 
This fact led to an increase in the yield mainly when quinoxalines are substituted by 
halogens in positions 6 and/or 7 of the ring. 
Compounds substituted by a cyclic amine on positions 6 and/or 7 of the quinoxaline 
ring were prepared by nucleophilic aromatic substitution of the corresponding 
quinoxaline. All the quinoxalines presented a chloro or fluoro substituted on positions 6 
and/or 7 of the ring as leaving group and different cyclic amines were used as 
nucleophiles. As expected, the fluoro acts as a better leaving group decreasing the 
reaction times in comparison with the chloro. The longer reaction times needed when a 
chloro was substituted on positions 6 and 7 of the heterocycle led to the generation of 
the mono-reduced quinoxaline (14 and 15) complicating the purification of the desired 
compounds.
37, 38
 Different synthetic methodologies were used with the aim of preparing 
the desired compounds. When the reaction was carried out in N,N-DMF, the fluoro 
could be replaced not only by the cyclic amine but also by the solvent (compound 12) 
making more difficult the isolation of the desired compound. Moreover, the use of 
reflux would facilitate the generation of 1-N-oxide quinoxaline derivatives (14 and 15). 
N,N-DMF was substituted by acetonitrile that could be used as aprotic polar solvent that 
would avoid the aforementioned difficulties.
39-41
 Finally, triethylamine was used as base 
and 6 compounds were prepared using these conditions (5, 6, 8-11). All of the 
compounds were fully characterized by infrared spectroscopy, nuclear magnetic 
resonance and elemental microanalyses (See Supplementary material). 
Compounds were assayed against the epimastigote form of T. cruzi, Tulahuen 2 strain in 
order to determine the percentage of growth inhibition (PGI) at 25 M and the IC50. 
Compounds showing IC50 lower than Nifurtimox (IC50=7.7 M) are considered active 
and would be considered for further testing.
42
 Five compounds were selected and their 
unspecific cytotoxicity and genotoxicity were studied before moving on to advanced 
studies. Cytotoxicity was assayed in Vero cells and the IC50 was determined from the 
dose-response curve. The Selectivity Index (SI) is expressed as the ratio of IC50 in 
mammalian cells to IC50 in epimastigote. The mutagenic capacity of the selected 
compounds was studied using the SOS/umu screening test. 
The primary screening data for all compounds at 25 M are shown in Table 1. The 
results demonstrate that 13 out of the 15 evaluated compounds presented PGI higher 
than 80%. Moreover, 10 of the derivatives showed IC50 values lower than the reference 
drugs Nfx and Bzn, presenting 4 of them IC50 values lower than 1.5 M. 
Analysis of the activity data presented in Table 1 reveals that substitution of a halogen 
atom, on position 7 of the quinoxaline, by a cyclic amine led to a decrease of the in vitro 
anti-T. cruzi activity. This behavior can be observed when comparing compounds 5-9 
with their parent compound A or, in general terms, comparing with compounds 1-4. 
If considering mono or di-substitution by cyclic amines no conclusion can be achieved. 
Di-substituted derivatives 11 and 13 showed lower PGI and higher IC50 than their 
mono-substituted analogues 8 and 12. Meanwhile, derivative 10 presented very 
interesting data, even better than its mono-substituted analogue 5. 
Regarding the type of amine substituted on position 6 and/or 7, derivatives that present 
a piperidine on these positions (compounds 5 and 10) stand out with IC50 (2.6 and 2.3 
M, respectively) much better than the reference drugs. When piperidine is substituted 
by its bioisosteres morpholine or tiomorpholine or a hydroxyl moiety is substituted on 
position 6, the in vitro activity of these derivatives decreases (compound 5 vs. 6-8). It 
can be confirmed that the most decisive structural requirement, in terms of in vitro 
biological activity, is the presence of electron withdrawing substituents on positions 6 
and/or 7. On the other hand, substitution on position 2 of the quinoxaline ring seems not 
to play such an important role on biological activity as previously observed.
27, 36
 This 
behavior can also be observed in compounds 1-4 that present the best activity data. 
Table 1. In vitro trypanosomicidal activity of quinoxaline derivatives. 















 COCH3 F F 100 0.39 
1 COPh-p-F H Cl 86.1 1.0 
2 COPh-p-F Cl Cl 89.3 1.3 
3 COPh-p-F H F 95.6 1.1 
4 COPh-p-F F F 91.8 0.6 
5 COCH3 F  96.9 2.6 
6 COCH3 F  100 6.4 
7 COCH3 F  83.4 2.0 
8 COCH3 F  84.9 6.3 
9 COCH3 F  93.4 5.3 
10 COCH3   100 2.3 
11 COCH3   15.7 >25 
12 COCH(CH3)2 N(CH3)2  86.0 10.7 
13 COCH(CH3)2   66.3 17.0 
14
[d] 
CO-2-furyl Cl  91.7 12.1 
15
[d]
 COOCH2CH3 Cl  54.6 >25 
Nfx    100 7.7 
Bnz    100 8.0 
[a] Previously reported in 
27
. [b] Percentage of growth inhibition of 
epimastigote growth of Tulahen 2 strain, dose = 25M. [c] Concentration 
(in M) that inhibits 50% of epimastigote form of T. cruzi growth. The 
results are the mean of three independent experiments with an SD less than 
10% in all cases. [d] quinoxaline-1-N-oxide 
Throughout the activity optimization process we were mindful of the importance of a 
good toxicological profile that would guarantee not only a potent compound but also a 
safe drug. Therefore and owing to the interesting in vitro trypanosomicidal activity 
showed by the quinoxaline derivatives, 5 compounds (3-5, 10 and 14) were selected 
considering their IC50 value (compounds 3, 4 and 5) and from a structural point of view 
compound 10 was included due to its significant activity and in order to study the 
influence of the substitution of an halogen by an amine. Compound 14 was selected to 
evaluate the influence of the N-oxide on the toxicological profile of these derivatives. 
The in vitro cytotoxicity was studied using the tetrazolium-based colorimetric assay 
(MTT assay) in Vero cells. The IC50 values after 48 h of incubation are shown in Table 
2. The selective indexes (SI) were calculated as the ratio of IC50 in Vero cells to IC50 in 
T. cruzi Tulahuen 2 strain. 
Moreover, the compounds were tested in the SOS/umu screening test for their 
genotoxicity capacity. The results obtained from the SOS/umu screening test for the 
selected compounds (3-5, 10, 14) with and without metabolic activation are shown in 
Table 2. The evaluated doses of each compound were determined in previous toxicity 
studies on the test system. 










(M) SI -S9 +S9 
3 95.6 1.1 4.4 4.0 + + 
4 91.8 0.6 3.0 5.0 + + 
5 96.9 2.6 15.2 5.8 + + 
10 100 2.3 4.5 1.7 - - 
14 91.7 12.1 454.7 37.6 + + 
 
Regarding the unspecific cytotoxicity assay, 4 compounds (3-5 and 10) presented SI 
lower than 10. Compound 14 was the only one that presented a SI value higher than 25 
and could be considered moderately selective. This increase in the SI is mainly due to 
the low non specific cytotoxicity presented by this compound which does not present a 
N-oxide moiety, generally related with toxic effects, in one of the nitrogens of the 
quinoxaline heterocycle. 
The SOS/umu screening test revealed that 4 compounds (3-5 and 14) were genotoxic 
with and without metabolic activation and compound 10 was not genotoxic in any of the 
tested conditions. Interestingly, the absence of a fluoro substituent in the quinoxaline 
system was the only condition to loss the mutagenic capacity. From the genotoxicity 
point of view, this could point out the quinoxaline 10 for further studies. 
According to the SI values showed in Table 2 compound 14 could be considered for 
further testing so that its activity against the trypomastigote and amastigote forms of T. 
cruzi should be explored. However, compound 14 was genotoxic in both tested 
conditions, with and without metabolic activation. Therefore, none of the tested 
compounds will continue for further development. 
In conclusion, thirteen new 1,4-di-N-oxide and two 1-N-oxide quinoxaline derivatives 
were synthesized and evaluated against T. cruzi identifying new derivatives with potent 
in vitro anti-T. cruzi activity. Ten out of the fifteen evaluated compounds resulted more 
active than the reference drugs Nfx and Bnz. Four of them stand out with IC50 lower 
than 1.5 M. Due to the toxicity issues usually associated to this family of compounds; 
unspecific cytotoxicity assay and a genotoxicity screening test were included in the very 
early stages of the project. Four out of the five tested compounds were mutagenic in 
both tested conditions. Compound 10 was not mutagenic; however, its low SI value 
(SI=1.7) led us to discontinue the biological studies of this family of compounds against 
T. cruzi. An appropriate toxicological profile study should consider not only unspecific 
cytotoxicity as usual but also mutagenicity issues. Including toxicological studies in the 
very early phases of biological evaluation would allow reducing costs and time in the 
overall drug discovery process. 
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